Royal London Asset Management Ltd. Sells 170,217 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Royal London Asset Management Ltd. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 706,765 shares of the biopharmaceutical company's stock after selling 170,217 shares during the quarter. Royal London Asset Management Ltd. owned about 0.06% of Gilead Sciences worth $65,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. HHM Wealth Advisors LLC lifted its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC grew its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Cantor Fitzgerald reissued a "neutral" rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Morgan Stanley upped their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 11th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Finally, Oppenheimer upped their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Remove Ads

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 302,785 shares of company stock worth $30,503,250. Company insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 0.3 %

Shares of GILD stock traded down $0.34 during mid-day trading on Monday, reaching $106.74. 8,562,938 shares of the company's stock traded hands, compared to its average volume of 6,800,396. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company's 50-day moving average price is $103.68 and its 200-day moving average price is $93.96. The company has a market cap of $132.93 billion, a P/E ratio of 288.49, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.96%. Gilead Sciences's payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.